Benzinga's Top Upgrades, Downgrades For April 2, 2018


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Top Upgrades

  • Deutsche Bank upgraded J.B. Hunt Transport Services, Inc. (NASDAQ:JBHT) from Hold to Buy. Hunt shares rose 1.94 percent to close at $117.15 on Thursday.
  • Wells Fargo upgraded Discovery Communications, Inc. (NASDAQ:DISCA) from Market Perform to Outperform. Discovery shares rose 1.23 percent to close at $21.43 on Thursday.
  • Analysts at RBC Capital upgraded Automatic Data Processing, Inc. (NASDAQ:ADP) from Sector Perform to Outperform. ADP rose 1.24 percent to $114.89 in pre-market trading.
  • BMO Capital upgraded Greif, Inc. (NYSE:GEF) from Market Perform to Outperform. Greif shares fell 0.38 percent to $52.05 in pre-market trading.
  • Goldman upgraded Northern Trust Corporation (NASDAQ:NTRS) from Neutral to Buy. Northern Trust shares rose 0.65 percent to $103.80 in pre-market trading.
  • Deutsche Bank upgraded Union Pacific Corporation (NYSE:UNP) from Hold to Buy. Union Pacific shares rose 2.81 percent to close at $134.43 on Thursday.
  • Jefferies upgraded Tesla, Inc. (NASDAQ:TSLA) from Underperform to Hold. Tandem Diabetes Care shares fell 4.46 percent to $254.25 in pre-market trading.
  • Keefe, Bruyette Woods upgraded Allstate Corporation (NYSE:ALL) from Underperform to Market Perform. Allstate shares rose 0.20 percent to close at $94.80 on Thursday.
  • RBC Capital upgraded Paychex, Inc. (NASDAQ:PAYX) from Underperform to Sector Perform. Paychex shares rose 1.63 percent to close at $61.59 on Thursday.
  • Bank of America upgraded Baker Hughes, a GE company (NYSE:BHGE) from Neutral to Buy. Baker Hughes shares rose 1.22 percent to $28.11 in pre-market trading.


Top Downgrades

  • Morgan Stanley downgraded Fitbit, Inc. (NYSE:FIT) from Equal-Weight to Underweight. Fitbit shares fell 5.29 percent to $4.83 in pre-market trading.
  • Bank of America downgraded Sonoco Products (NYSE:SON) from Buy to Neutral. Sonoco shares fell 1.13 percent to $47.95 in pre-market trading.
  • Analysts at Baird downgraded National Instruments Corporation (NASDAQ:NATI) from Outperform to Neutral. National Instruments shares rose 2.68 percent to close at $50.57 on Thursday.
  • Barclays downgraded XL Group Ltd (NYSE:XL) from Overweight to Equal-Weight. XL shares fell 0.16 percent to close at $55.26 on Thursday.
  • Bank of America downgraded Greif, Inc. (NYSE:GEF) from Buy to Neutral. Greif shares fell 0.38 percent to $52.05 in pre-market trading.
  • Bank of America downgraded Domtar Corporation (NYSE:UFS) from Buy to Neutral. Domtar shares fell 1.27 percent to $42.00 in pre-market trading.
  • Raymond James downgraded RSP Permian, Inc. (NYSE:RSPP) from Strong Buy to Market Perform. RSP Permian shares rose 4.18 percent to close at $46.88 on Thursday.


Top Initiations

  • Ascendiant Capital initiated coverage on IsoRay, Inc. (NYSE:ISR) with a Buy rating. The price target for IsoRay is set to $1. IsoRay shares closed at $0.4206 on Thursday.
  • Analysts at H.C. Wainwright initiated coverage on SELLAS Life Sciences Group, Inc (NASDAQ:SLS) with a Buy rating. The price target for SELLAS Life Sciences is set to $11. SELLAS Life Sciences closed at $3.45 on Thursday.
  • Barclays initiated coverage on BioXcel Therapeutics, Inc. (NASDAQ:BTAI) with an Overweight rating. The price target for BioXcel Therapeutics is set to $15. BioXcel Therapeutics shares closed at $10.24 on Thursday.
  • H.C. Wainwright assumed coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating. The price target for Nektar Therapeutics is set to $125. Nektar Therapeutics shares closed at $106.26 on Thursday.
  • Analysts at Canaccord Genuity initiated coverage on BioXcel Therapeutics, Inc. (NASDAQ:BTAI) with a Buy rating. The price target for BioXcel Therapeutics is set to $21. BioXcel Therapeutics shares closed at $10.24 on Thursday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: UpgradesDowngradesInitiationPre-Market OutlookAnalyst RatingsElectronic Equipment ManufacturersInformation TechnologyInitiationstop upgrades